Showing results (11-20 of 180) with videos related to

Sort By:
Pageof 18
Physiological Reports|March 22, 2023
Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heartRoss T Lindsay, Philip Ambery, Lutz Jermutus, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 30, 2008
Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human Fc gammaRIStephane Bonetto, Loredana Spadola, Andrew G Buchanan, et al.
Drug Discovery Today|March 22, 2022
Exploiting protease activation for therapyChloe Bleuez, Wolfgang F Koch, Carole Urbach, et al.
European Biophysics Journal : EBJ|May 25, 2002
Ligand binding of a ribosome-displayed protein detected in solution at the single molecule level by fluorescence correlation spectroscopyLutz Jermutus, Reto Kolly, Zeno Földes-Papp, et al.
Nature Cancer|February 22, 2023
Advances in antibody-based therapy in oncologySacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, et al.
Nature Communications|February 10, 2023
Evolution of protease activation and specificity via alpha-2-macroglobulin-mediated covalent capturePhilipp Knyphausen, Mariana Rangel Pereira, Paul Brear, et al.
Biotechnology and Bioengineering|March 30, 2006
Parallel, high-throughput purification of recombinant antibodies for in vivo cell assaysDavid Bannister, Andrew Wilson, Leah Prowse, et al.
Journal of the American Chemical Society|August 9, 2002
In vitro selection for catalytic activity with ribosome displayPatrick Amstutz, Joelle N Pelletier, Armin Guggisberg, et al.
Diabetes Care|May 21, 2021
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b StudyRajaa Nahra, Tao Wang, Kishore M Gadde, et al.
Diabetes, Obesity & Metabolism|April 28, 2021
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetesMichiko Asano, Akiko Sekikawa, Hyosung Kim, et al.
Pageof 18